Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
18 hedge funds and large institutions have $392K invested in Aridis Pharmaceuticals Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 5 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
10% less funds holding
Funds holding: 20 → 18 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
64% less capital invested
Capital invested by funds: $1.09M → $392K (-$700K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$36.6K |
| 2 |
HF
HRT Financial
New York
|
+$13K |
| 3 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
+$4.61K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.4K |
| 5 |
VF
Virtu Financial
New York
|
+$2.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$672K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$89.6K |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$11.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.25K |
| 5 |
Jane Street
New York
|
-$4.82K |
ARDS Hedge Fund Activity: Q2 2023 in Review
18 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q2 2023, worth a combined $392K — down 64% from $1.09M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ARDS and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 5 added.
The largest buyer was State Street, adding an estimated $36.6K. The largest seller was Sabby Management, exiting entirely with an estimated $672K sold.
- 18 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q2 2023, down from 20 in Q1 2023.
- Funds reported $392K of Aridis Pharmaceuticals Inc. Common Stock stock for Q2 2023, down 64% quarter-over-quarter.
- 3 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q2 2023 and 5 closed out, a net change of -2 holders.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q2 2023 was State Street, an estimated $36.6K added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q2 2023 was Sabby Management, an estimated $672K sold.
Based on aggregated 13F filings for Q2 2023.